Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference
Altimmune plans a webcast fireside chat at the Wells Fargo healthcare conference, offering investors online access to management’s remarks.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Altimmune (ALT) will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on September 10, 2026, at 9:30 a.m. ET.
The late clinical-stage biopharmaceutical company is developing pemvidutide for serious liver diseases, and will provide webcast access to the session via the Events section of its website.
Details
News Market Reaction – ALT
On Sep 3, the day this news came out, ALT closed 1.52% below the previous close. Our momentum scanner recorded 17 alerts in the available session data. Relative volume reached 1.6x the daily average during tracking.
Data tracked by StockTitan Argus for the Sep 3 session.
Key Figures
- Announcement date
- September 3, 2026
- Article dateline
- Conference edition
- 21st annual
- Wells Fargo Healthcare Conference
- Conference date
- September 10, 2026
- Scheduled fireside chat
- Fireside chat time
- 9:30 a.m. ET
- September 10, 2026
Historical Context
-
Quarterly results and business update coincided with a negative 24-hour price reaction.
-
Announcement scheduled second-quarter results and a management business update for August 12.
-
Company began enrolling patients in the global PERFORMA Phase 3 MASH trial.
-
RECLAIM met its primary endpoint and reported favorable secondary alcohol-use-disorder results.
-
IMPACT data showed metabolic improvements across weight, lipids, and other measures.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
GAITHERSBURG, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Thursday, September 10, 2026, at 9:30 a.m. ET.
A webcast of the fireside chat will be available via the Events section of the Altimmune website.
About Altimmune
Altimmune is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company’s lead candidate, pemvidutide, is a unique dual-action investigational therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on X
Investor Contact:
Luis Sanay, CFA
Vice President, Investor Relations
ir@altimmune.com
Media Contact:
Real Chemistry
altimmune@realchemistry.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.